Compare iShares MSCI Malaysia ETF (EWM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI Malaysia ETF trades at $26.86 (market cap $241.37M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 15.5× iShares MSCI Malaysia ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 68 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWM | TNGX | |
|---|---|---|
Market Cap | $241.37M | $3.75B |
Volume | 74,129 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $32.90 |
52-Week Low | $25.47 | $7.50 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM trades at $26.96, up 0.63% today, but technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure. Key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Recent news highlights external risks, such as regional haze-related disruptions affecting operations in Malaysia, which could impact investor confidence.
The outlook remains cautious due to weak technicals and limited fundamental data. Risks include environmental disruptions and market volatility. Investment opportunities hinge on upcoming financial disclosures to validate growth prospects, while current sentiment leans bearish amid uncertainty.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
